SEARCH

SEARCH BY CITATION

References

  • 1
    Kusunoki S, Kaida K. Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders. J Neurochem. 2011; 116: 82832.
  • 2
    Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers. 2006; 22: 197206.
  • 3
    Beyer NH, Lueking A, Kowald A, Frederiksen JL, Heegaard NH. Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol. 2012; 242: 2632.
  • 4
    Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002; 2: 8595.
  • 5
    Rathjen FG, Wolff JM, Chang S, Bonhoeffer F, Raper JA. Neurofascin: a novel chick cell-surface glycoprotein involved in neurite-neurite interactions. Cell. 1987; 51: 8419.
  • 6
    Volkmer H, Hassel B, Wolff JM, Frank R, Rathjen FG. Structure of the axonal surface recognition molecule neurofascin and its relationship to a neural subgroup of the immunoglobulin superfamily. J Cell Biol. 1992; 118: 14961.
  • 7
    Barclay AN. Membrane proteins with immunoglobulin-like domains–a master superfamily of interaction molecules. Semin Immunol. 2003; 15: 21523.
  • 8
    Williams AF, Barclay AN. The immunoglobulin superfamily–domains for cell surface recognition. Annu Rev Immunol. 1988; 6: 381405.
  • 9
    Yoshihara Y. Immunoglobulin Superfamily Cell Adhesion Molecules. In: Mark D, Binder NH, Windhorst U, eds. Encyclopedia of Neuroscience. Berlin, Heidelberg: Springer, 2009: pp. 19236.
  • 10
    Kriebel M, Wuchter J, Trinks S, Volkmer H. Neurofascin: a switch between neuronal plasticity and stability. Int J Biochem Cell Biol. 2012; 44: 6947.
  • 11
    Nagase T, Ishikawa K, Suyama M, Kikuno R, Miyajima N, Tanaka A, et al. Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1998; 5: 27786.
  • 12
    Hassel B, Rathjen FG, Volkmer H. Organization of the neurofascin gene and analysis of developmentally regulated alternative splicing. J Biol Chem. 1997; 272: 287429.
  • 13
    Volkmer H, Leuschner R, Zacharias U, Rathjen FG. Neurofascin induces neurites by heterophilic interactions with axonal NrCAM while NrCAM requires F11 on the axonal surface to extend neurites. J Cell Biol. 1996; 135: 105969.
  • 14
    Pruss T, Kranz EU, Niere M, Volkmer H. A regulated switch of chick neurofascin isoforms modulates ligand recognition and neurite extension. Mol Cell Neurosci. 2006; 31: 35465.
  • 15
    Kriebel M, Metzger J, Trinks S, Chugh D, Harvey RJ, Harvey K, et al. The cell adhesion molecule neurofascin stabilizes axo-axonic GABAergic terminals at the axon initial segment. J Biol Chem. 2011; 286: 2438593.
  • 16
    Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron. 2005; 48: 73742.
  • 17
    Ango F, di Cristo G, Higashiyama H, Bennett V, Wu P, Huang ZJ. Ankyrin-based subcellular gradient of neurofascin, an immunoglobulin family protein, directs GABAergic innervation at purkinje axon initial segment. Cell. 2004; 119: 25772.
  • 18
    Ratcliffe CF, Westenbroek RE, Curtis R, Catterall WA. Sodium channel beta1 and beta3 subunits associate with neurofascin through their extracellular immunoglobulin-like domain. J Cell Biol. 2001; 154: 42734.
  • 19
    Charles P, Tait S, Faivre-Sarrailh C, Barbin G, Gunn-Moore F, Denisenko-Nehrbass N, et al. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol. 2002; 12: 21720.
  • 20
    Thaxton C, Pillai AM, Pribisko AL, Labasque M, Dupree JL, Faivre-Sarrailh C, et al. In vivo deletion of immunoglobulin domains 5 and 6 in neurofascin (Nfasc) reveals domain-specific requirements in myelinated axons. J Neurosci. 2010; 30: 486876.
  • 21
    Tait S, Gunn-Moore F, Collinson JM, Huang J, Lubetzki C, Pedraza L, et al. An oligodendrocyte cell adhesion molecule at the site of assembly of the paranodal axo-glial junction. J Cell Biol. 2000; 150: 65766.
  • 22
    Pomicter AD, Shroff SM, Fuss B, Sato-Bigbee C, Brophy PJ, Rasband MN, et al. Novel forms of neurofascin 155 in the central nervous system: alterations in paranodal disruption models and multiple sclerosis. Brain. 2010; 133: 389405.
  • 23
    Zonta B, Tait S, Melrose S, Anderson H, Harroch S, Higginson J, et al. Glial and neuronal isoforms of Neurofascin have distinct roles in the assembly of nodes of Ranvier in the central nervous system. J Cell Biol. 2008; 181: 116977.
  • 24
    Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med. 2007; 204: 236372.
  • 25
    Pruss H, Schwab JM, Derst C, Gortzen A, Veh RW. Neurofascin as target of autoantibodies in Guillain-Barre syndrome. Brain 2011; 134: e173; author reply e74.
  • 26
    Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barre syndrome. J Peripher Nerv Syst. 2012; 17: 6271.
  • 27
    Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012; 79: 22418.
  • 28
    Kamm C, Zettl UK. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev. 2012; 11: 196202.
  • 29
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69: 292302.
  • 30
    Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991; 41: 6178.
  • 31
    Thomas PK, Walker RW, Rudge P, Morgan-Hughes JA, King RH, Jacobs JM, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain. 1987; 110(Pt 1): 5376.
  • 32
    Pirko I, Kuntz NL, Patterson M, Keegan BM, Weinshenker BG, Rodriguez M. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Neurology. 2003; 60: 16979.
  • 33
    Zephir H, Stojkovic T, Latour P, Lacour A, de Seze J, Outteryck O, et al. Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry. 2008; 79: 10329.
  • 34
    Kawamura N, Yamasaki R, Yonekawa T, Matsushita T, Kusunoki S, Nagayama S, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013; 81: 71422.
  • 35
    Matsuse D, Ochi H, Tashiro K, Nomura T, Murai H, Taniwaki T, et al. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis. Intern Med. 2005; 44: 6872.